ArticleEFSA journal. European Food Safety Authority2026
Assessment of the feed additive consisting of astaxanthin (2a161j) for fish, crustaceans and ornamental fish for the renewal of its authorisation (BASF SE, DSM Nutritional Products Ltd., JYB Europe BV, NHU EUROPE GmbH).
Article in EFSA journal. European Food Safety Authority, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Assessment of the feed additive consisting of astaxanthin (2a161j) for fish, crustaceans and ornamental fish for the renewal of its authorisation (BASF SE, DSM Nutritional Products Ltd., JYB Europe BV, NHU EUROPE GmbH).EFSA journal. European Food Safety Authority · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Following a request from the European Commission, EFSA was asked to deliver a scientific opinion on the assessment of the application for the renewal of the authorisation of astaxanthin as a sensory additive for fish, crustaceans and ornamental fish. The applicants provided evidence that the additive currently on the market complies with the existing conditions of authorisation. There is no new evidence that would lead the EFSA Panel on Additives and Products or Substances used in Animal Feed to reconsider its previous conclusions regarding the safety of the additive. Therefore, astaxanthin remains safe for the target species, consumers and environment under the authorised conditions of use. Regarding safety for the user, astaxanthin is not irritant to skin or eyes and is not a dermal sensitiser. The dispersible powder formulation containing 10% astaxanthin is not irritant to skin and eye but should be considered a dermal and respiratory sensitiser, and exposure of users by respiratory and dermal routes is considered a risk. No conclusions can be drawn on the other preparations containing astaxanthin. There is no need for assessing the efficacy of the additive in the context of the renewal of the authorisation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.